VBL Therapeutics (Nasdaq: VBLT) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

Our lead product candidate from our oncology program, VB-111, is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors.

VB-111 is given through a simple IV infusion once every two months.  So far, VB-111 showed activity in three Phase 2 studies – in rGBM, Ovarian cancer and Thyroid cancer.  VB-111 was well-tolerated in over 300 cancer patients. It has potential for combination therapy with other drugs.


VB-111 utilizes genetically targeted therapy to destroy the newly formed, or angiogenic, blood vessels which nourish the tumor, leading to tumor starvation. In addition, VB-111 induces a local anti-tumor immune response.

Ongoing Clinical Trials

VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA. Top-line data are expected in 1Q2018. 

VBL Therapeutics’ Phase 3 OVAL study in recurrent platinum-resistant ovarian cancer was launched in December 2017. 

 For tumor-specific information, please click on the relevant indication.